肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Radiology：胖不胖可能决定透明细胞肾癌患者整体生存期

2018-04-20 shaosai MedSci原创

透明细胞肾癌脂肪糖酵解
关注

本研究旨在验证是否男女腹腔内脏脂肪含量差异及肿瘤葡萄糖代谢能有助于预测透明细胞肾癌（RCC）的结果，并将结果发表在Radioloy上。

本研究旨在验证是否男女腹腔内脏脂肪含量差异及肿瘤葡萄糖代谢能有助于预测透明细胞肾癌（RCC）的结果，并将结果发表在Radioloy上。

本研究纳入了222例有透明细胞RCC的患者，利用CT身体脂肪被分为皮下脂肪及内脏脂肪区域（VFAs），并行全身脂肪校正来得到相对VFA（rVFA）和相对皮下脂肪区域。收集患者的39个糖酵解基因的表达特征来确定代谢的性别差异并与rVFA进行比较。分析透明细胞RCC主要突变与rVFA和肿瘤糖酵解特征的相关性。

结果为， rVFA超过30.9%的女性患者的死亡风险更高(HR：3.66 [95% CI： 1.64， 8.19]) vs 1.13 ([95% CI： 0.58， 2.18] for men， P = .028)。糖酵解基因表达在男女间分层，低rVFA和低糖酵解在19例女性患者中有较好的整体生存期(P < .001)。SETD2和BAP1突变会独特地增加女性患者肿瘤糖酵解(分别为P = .036、.001)。在高rVFA和低rVFA患者间肿瘤突变无统计学差异。

本研究表明，内脏脂肪男女差异和和肿瘤葡萄糖代谢可能会对透明细胞RCC患者提供新的风险分层系统。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=309815, encodeId=34b2309815d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Fri Apr 27 14:57:50 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378169, encodeId=55ac13e8169e5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 22 08:45:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307839, encodeId=5a8a30e8398e, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:36 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307637, encodeId=e77030e63760, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Apr 20 18:29:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-27 1201e5c5m39暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=309815, encodeId=34b2309815d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Fri Apr 27 14:57:50 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378169, encodeId=55ac13e8169e5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 22 08:45:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307839, encodeId=5a8a30e8398e, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:36 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307637, encodeId=e77030e63760, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Apr 20 18:29:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-22 仁者大医

    #生存期#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=309815, encodeId=34b2309815d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Fri Apr 27 14:57:50 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378169, encodeId=55ac13e8169e5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 22 08:45:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307839, encodeId=5a8a30e8398e, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:36 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307637, encodeId=e77030e63760, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Apr 20 18:29:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-21 梦想起航ing

    不错.学习了.做笔记了.谢谢分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=309815, encodeId=34b2309815d7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Fri Apr 27 14:57:50 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378169, encodeId=55ac13e8169e5, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 22 08:45:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307839, encodeId=5a8a30e8398e, content=不错.学习了.做笔记了.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sat Apr 21 08:00:36 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307637, encodeId=e77030e63760, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Apr 20 18:29:00 CST 2018, time=2018-04-20, status=1, ipAttribution=)]
    2018-04-20 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

相关资讯

JCO：HIF-2α拮抗剂PT2385治疗晚期透明细胞肾癌

大部分透明细胞肾癌患者中均存在HIF-2α不稳定。PT2385是第一类HIF-2α拮抗剂。JCO近期发表了一篇文章，报道PT2385治疗透明细胞肾癌的Ⅰ期临床试验结果。

Radiology：肾脏小肿块--标准化MR成像诊断法则叫板病理！

本研究旨在评价多参数磁共振（MR）成像标准化诊断法则在识别小(≤4 cm)肾脏肿块(SRMs)组织病理学类型的诊断价值及观察者间一致性，并将结果发表在Radiology上。